Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector - Infection
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
India throws rule book at 'superbug' scientists
02 September 2010
Indian physicians who were involved in the controversial "superbug" NDM-1 study that was published in Lancet Infectious Diseases last month have been asked to confirm whether they followed various national guidelines and procedures required for the ...
Japan to subsidise Takeda's cell cultured flu vaccine R&D
02 September 2010
The Japanese government is to provide a multi-million dollar subsidy to the country's largest pharma company for the development of cell cultured vaccines for pandemic influenza. Following an application for the support, Takeda has been notified ...
Ranbaxy opens second plant in South Africa
01 September 2010
Ranbaxy Laboratories has opened its second manufacturing facility in South Africa at Roodepoort, Johannesburg, at an investment of $30 million. It will manufacture a range of products including analgesics, cold, cough and flu preparations, ...
Daiichi Sankyo raises first-half outlook on strong generic valaciclovir sales
31 August 2010
Daiichi Sankyo has raised its sales and profit guidance for the first half of the current fiscal year on expectations of a better than expected performance from its Ranbaxy generics subsidiary. The Japanese firm is now forecasting a consolidated net ...
US HHS calls for $2 billion overhaul in biodefence tools, with improved vaccine preparedness
24 August 2010
The US Health and human services (HHS) secretary Kathleen Sebelius is calling for about $2 billion to be spent in the coming years for an overhaul of the nation's biodefence measures and pandemic defence programme – including large chunks to ...
 
Liver cancer becomes more preventable and treatable
12 August 2010
New drugs to treat viral hepatitis infection, coupled with renewed interest from companies in developing therapies to treat liver cancer following Nexavar's approval, have improved prospects for both ...
Scrip Asia 100 - Manufacturing marvels
29 June 2010
Asia is home to countless companies specialising in pharmaceutical manufacturing. We think the following stand out from the crowd. Centre for Research and Production of Vaccines and Biology ...
Scrip Asia 100 - GSK takes the flexible approach to Asian growth
29 June 2010
GlaxoSmithKline's approach to growing its business across the Asia-Pacific region recognises the need for distinct strategies tailored to each national market. This may involve a blend of price cuts, ...
 
Face to face: Ex-Novartis manager takes two-step approach to women's health at Lumavita
12 January 2010
Many pharmaceutical and biotech companies devote themselves to the discovery and development of novel drugs for unmet medical needs. However, with R&D costs and regulatory hurdles multiplying, and ...
Basilea set for success as Toctino roll-out sees revenues surge
26 October 2009
Basilea Pharmaceuticals is currently targeting profitability by around 2012 and has prioritised its research programmes to ensure it becomes a successful hospital and speciality products-focused ...
Cellectis: Partner search is on for meganuclease technology
25 September 2009
The French genome engineering company Cellectis is generating good publicity for its meganuclease technology following its recent deal with Servier for the use of its ∏10 research kit. Scrip's Sita ...
 
Private investment round-up: May 2010
25 June 2010
Scrip analysis highlighted 11 private companies that secured financing last month, three fewer than in April. The total raised by these companies fell by 29% to $247 million as the amount of US ...
Private investment round-up: March 2010
14 April 2010
The private investment market was dominated by a UK firm for the first time in many years as Archimedes Pharma far outreached US competitors, a Scrip analysis has found. Archimedes's £65 million ...
Commentary: Asia's largest pharma event remarkably upbeat
08 July 2009
If spotless stainless steel manufacturing equipment and high-tech hardware stretching as far as the eye can see is your thing, the BioForum & BioExpo Japan exhibition held in Tokyo last week was the ...
 
Clinical immunotoxicity of therapeutic proteins
11 May 2009
Therapeutic proteins are proteins engineered in the laboratory for pharmaceutical use. Although they tend to offer a better safety margin than most synthetic small molecules because they are ...
Clevudine: a promising therapy for the treatment of chronic hepatitis B
01 December 2008
Chronic hepatitis B virus (HBV) infection, affecting ∼ 350 million people worldwide, is associated with significant morbidity and mortality. In the past 10 years, hepatitis B therapy research has led ...
Meningococcal tetravalent conjugate vaccine
01 December 2008
Background: Neisseria meningitidis is a leading cause of meningitis and sepsis worldwide. Since 1981, a tetravalent meningococcal polysaccharide vaccine has been available in the US but it has been ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm